Research reference · 10 mg topical research

SNAP-8 Dosage: 10 mg Topical Research Guide

Written by PeptideDosages Editorial Team Published Updated

SNAP-8 dosage is best expressed as the concentration of active acetyl octapeptide-3 in a finished topical research formulation. Human research has evaluated SNAP-8 in creams, multi-peptide serums, and purpose-built dissolving microneedle patches. The calculator below converts a 10 mg vial into actual active-peptide concentrations for topical cream, gel, or serum research.

On this page
  1. Quick reference
  2. Dosage and formulation chart
  3. Supplies needed
  4. Vial and research context
  5. Topical Research Quick Reference
  6. Human SNAP-8 Research Formulations
  7. SNAP-8 Topical Research Protocol Overview
  8. Topical Preparation Planning
  9. Read SNAP-8 Concentration Labels Carefully
  10. How SNAP-8 Is Proposed to Work
  11. Research Outcomes and Tolerability
  12. Study Design and Tracking
  13. Topical Application and Measurement Controls
  14. SNAP-8 Dosage FAQ
  15. Recommended Research Source
  16. Important Research Note
  17. References
  18. Related research, protocols, and guides

SNAP-8 Quick Reference (10 mg Vial)

Vial contents
10 mg SNAP-8
Whole 10 mg vial at 0.005%
200 g final batch weight
50 g batch at 0.005%
2.5 mg active peptide
Developer reference range
About 0.0015% to 0.005% active peptide In the finished topical formula
SNAP 8 10mg vial - SNAP 8 dosage protocol

Research context: For identity, mechanisms, human findings, limitations, and safety, read SNAP-8 Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

SNAP-8 Dosage Chart for a 10 mg Vial

Dosing & Topical Formulation Guide

Active-peptide concentration math for a SNAP-8 10 mg vial

Whole 10 mg Vial Concentration Calculator

These rows show the mathematical concentration produced when the complete 10 mg vial is distributed through a measured final batch weight. The 200 g to 666.7 g rows span the developer’s finished-active reference range. Smaller batches produce higher concentrations.

Final Batch Active Peptide Active % w/w ppm Research Context
30 g 10 mg 0.0333% w/w 333 ppm About 6.7 times the upper developer reference
50 g 10 mg 0.0200% w/w 200 ppm 4 times the upper developer reference
100 g 10 mg 0.0100% w/w 100 ppm 2 times the upper developer reference
200 g 10 mg 0.0050% w/w 50 ppm Matches 10% of the nominal 0.05% supplier solution
333.3 g 10 mg 0.0030% w/w 30 ppm Mid-range calculation
666.7 g 10 mg 0.0015% w/w 15 ppm Matches 3% of the nominal 0.05% supplier solution

Formula: Active percent w/w = peptide mg divided by final batch grams divided by 10. Parts per million = peptide mg divided by final batch grams multiplied by 1,000.

Small-Batch SNAP-8 Research Calculations

A typical 30 g or 50 g topical batch requires a measured portion of the vial to match the 0.0015% to 0.005% active reference range.

Final Batch 0.0015% Active 0.0030% Active 0.0050% Active
30 g 0.45 mg 0.90 mg 1.50 mg
50 g 0.75 mg 1.50 mg 2.50 mg
100 g 1.50 mg 3.00 mg 5.00 mg
200 g 3.00 mg 6.00 mg 10.00 mg

Formula: Peptide mg needed = target percent multiplied by final batch grams multiplied by 10.

Worked 1 mg/mL Stock Measurement Example

If a validated formulation plan uses the complete 10 mg vial in a measured 10.0 mL final stock volume, the nominal stock concentration is 1 mg/mL. Each 1.0 mL contains 1.0 mg SNAP-8. The stock must use a compatible vehicle, and the transferred amount becomes part of the final batch.

Final Batch Stock for 0.0015% Stock for 0.0030% Stock for 0.0050%
30 g 0.45 mL 0.90 mL 1.50 mL
50 g 0.75 mL 1.50 mL 2.50 mL
100 g 1.50 mL 3.00 mL 5.00 mL

Important: This is measurement math, not a shelf-life claim. A base must accept the added aqueous phase without losing homogeneity or preservation. An analytical standard remained stable for 96 hours at 4 degrees C, but this does not validate a multiweek topical stock or cream[5].

How to Read the 3% to 10% SNAP-8 Range

The ingredient developer supplied SNAP-8 as a preserved aqueous blend containing approximately 0.05% acetyl octapeptide-3. Adding 3% to 10% of that solution gives 0.0015% to 0.005% actual peptide in the final product[6]. A raw 10 mg vial and a preserved commercial premix are not operationally interchangeable.

Trade Solution Peptide in Stock Final Active % Equivalent ppm
3% 0.05% 0.0015% 15 ppm
6% 0.05% 0.0030% 30 ppm
10% 0.05% 0.0050% 50 ppm

Concentration math does not validate homogeneity, preservation, pH, compatibility, skin delivery, or shelf life. Those controls belong to the finished formulation.

Supplies Needed

Use a complete, measured formulation set for each SNAP-8 topical research batch.

  • SNAP-8 10 mg research vial: Record lot number, identity, assay, purity, and certificate of analysis.
  • Validated cosmetic research base: A compatible cream, gel, or serum base with a documented formula and preservation system.
  • Compatible stock vehicle: Use only when a validated formulation plan requires a measured stock.
  • Calibrated analytical balance: Needed for final batch weight and direct mass measurements within its validated range.
  • Calibrated pipettes or positive-displacement tools: Needed when an accurately quantified liquid stock is used.
  • Clean mixing and transfer tools: A suitable vessel, spatula, transfer tools, and validated homogenization method.
  • pH measurement: A calibrated meter or validated narrow-range strips.
  • Clean handling supplies: Clean gloves, alcohol preparation materials, and a disinfected work surface.
  • Final container: A compatible opaque or airless container with a secure closure and measurable dispenser.
  • Label and batch log: Record active mass, final weight, concentration, vehicle, pH, container, date, storage, and observations.
  • Stability observation log: Track appearance, odor, separation, pH drift, container compatibility, and validated testing.
SNAP 8 10mg vial - SNAP 8 dosage protocol View Supplier

SNAP-8 Topical Research Context

  • Best documented conventional cream reference: About 0.005% active SNAP-8, equal to 50 ppm.
  • Developer reference range: About 0.0015% to 0.005% active peptide in the finished topical formula.
  • Whole 10 mg vial at 0.005%: 200 g final batch weight.
  • 50 g batch at 0.005%: 2.5 mg active peptide.
  • Human schedule context: Twice-daily cream application for 28 days in manufacturer testing.

The widely quoted 3% to 10% use level refers to a supplier solution containing about 0.05% SNAP-8. It equals roughly 0.0015% to 0.005% active peptide in the finished formula, not 3% to 10% pure peptide[4][6].

Topical Research Quick Reference

  • 10 mg in 200 g: 0.005% w/w or 50 ppm.
  • 10 mg in 333.3 g: 0.003% w/w or 30 ppm.
  • 10 mg in 666.7 g: 0.0015% w/w or 15 ppm.
  • 50 g batch at 0.005%: 2.5 mg active peptide.

Human SNAP-8 Research Formulations

Human evidence is topical or device-assisted. Conventional cream data come from ingredient-developer testing. Peer-reviewed studies used multi-active serums or dissolving microneedle patches, so their outcomes cannot be assigned to SNAP-8 alone.

Study Formulation Schedule Design Context Evidence Limit
Lipotec developer panel[6] Cream with 10% of a nominal 0.05% SNAP-8 solution, equal to about 0.005% active peptide Twice daily around the eye area for 28 days 17 women; silicone replicas and profilometry; about 35% mean and 63% maximum wrinkle-depth reduction reported Manufacturer-reported, not an independent peer-reviewed trial
Shin et al. (2024)[1] 350 micrometer dissolving patch with 0.03% SNAP-8, 5% AA2G, 4% cyclic LPA, and 90% HA Overnight nightly through day 14, then every third day through day 28 24 enrolled and 21 completed a split-face active-versus-placebo comparison Combination device; SNAP-8’s independent contribution cannot be isolated
Avcil et al. (2020)[2] HA microneedle patch with SNAP-8, other peptides, adenosine, and seaweed extracts 12-week study Fine lines, hydration, dermal density, thickness, and tolerability measures Multi-active product; SNAP-8 concentration was not disclosed in the abstract
Draelos et al. (2016)[3] Multi-peptide serum containing SNAP-8 within a supporting skincare regimen Morning and evening for 12 weeks after a 2-week washout 29 women; investigator grading and participant questionnaires Open label, no control, multiple peptides and supporting products
Moy et al. (2023)[4] Proprietary multi-peptide facial serum containing acetyl octapeptide-3 Twice daily for 12 weeks 31 women completed dermatologist grading, imaging, hydration, and questionnaires Uncontrolled, multi-ingredient, and company funded

SNAP-8 Topical Research Protocol Overview

Concentration and Schedule

  • Developer active reference: Approximately 0.0015% to 0.005% active SNAP-8.
  • Best documented conventional cream example: Approximately 0.005% active peptide.
  • Application context: Twice daily around the eye area for 28 days in manufacturer testing.
  • Academic serum context: Morning and evening or twice-daily use for 12 weeks in multi-ingredient studies.
  • Patch context: Overnight nightly through day 14, then every third day through day 28 in a manufactured multi-active patch.

Storage and Stability Controls

  • Follow the vial supplier’s lot-specific storage documentation before formulation.
  • Store the finished batch according to its validated base, preservative, pH, container, and stability plan.
  • Do not transfer the trade solution’s published shelf life to a raw-vial formulation.
  • An analytical standard remained stable for 96 hours at 4 degrees C, but that does not establish cosmetic-product shelf life[5].

Topical Preparation Planning

  1. Confirm active mass: Adjust the nominal 10 mg amount if the lot assay requires it.
  2. Select the research concentration: Keep the percentage attached to its source, vehicle, route, and schedule.
  3. Calculate peptide mass: Use the small-batch table for the selected final weight.
  4. Define the stock method: If the mass is below the balance’s reliable range, use an accurately quantified stock in a compatible vehicle under a validated plan.
  5. Transfer and mix: Include the complete measured stock in the final batch and use a validated method for uniform dispersion.
  6. Verify the batch: Record final weight, pH, appearance, packaging, dispensing amount, preservation controls, and testing.
  7. Label the study unit: Include concentration, batch ID, date, storage, and observation schedule.

Read SNAP-8 Concentration Labels Carefully

Raw peptide concentration and supplier solution concentration describe different measurements. A formula containing a percentage of a premixed supplier solution should also state the calculated acetyl octapeptide-3 concentration in the finished batch.

How SNAP-8 Is Proposed to Work

SNAP-8 is acetyl octapeptide-3, an eight-amino-acid peptide modeled on part of SNAP-25. Its sequence is Ac-EEMQRRAD-NH2[7]. The proposed cosmetic mechanism is interference with SNARE-complex assembly and calcium-dependent exocytosis. Direct SNAP-8 mechanism data are primarily developer-generated, so biological plausibility is not equivalent to proof of clinical muscle relaxation.

SNAP-8 is distinct from acetyl hexapeptide-8, also called Argireline. Argireline studies are related-peptide background, not direct SNAP-8 evidence.

Research Outcomes and Tolerability

  • Wrinkle measurements: Studies used silicone replicas, profilometry, three-dimensional imaging, or investigator grading.
  • Combination patch: Shin and colleagues reported improvements in selected wrinkle and skin-quality measures versus an HA-only patch, with no adverse effects reported during 28 days[1].
  • Multi-active patch: Avcil and colleagues reported product-level changes in fine lines, hydration, density, and thickness, with excellent tolerability[2].
  • Serum studies: Multi-ingredient studies reported selected appearance and hydration improvements, but the effect of SNAP-8 cannot be isolated[3][4].
  • Formulation safety: Tolerability of a commercial formula or manufactured patch does not establish preservation, uniformity, or safety of a new raw-vial formulation.

Study Design and Tracking

  • Define target area, measured amount, frequency, duration, and primary endpoint before the first observation.
  • Use consistent lighting, camera position, facial expression, and time of day for images.
  • Keep other skincare products and cosmetic procedures consistent or document each change.
  • Record dispensing mass or volume so each application is reproducible.
  • Track redness, itching, burning, swelling, dryness, eye exposure, pH drift, and product separation.

Topical Application and Measurement Controls

  • Measure the dispensed amount: Use a calibrated pump, positive-displacement tool, or before-and-after container weight.
  • Keep the target area consistent: Apply to the predefined external skin area and prevent direct eye or mucosal contact.
  • Control the vehicle: Record the base formula because it affects spread, stability, preservation, and delivery.
  • Do not equate delivery systems: A 0.03% dissolving microneedle patch is not equivalent to a 0.03% intact-skin cream[1][5].

SNAP-8 Dosage FAQ

What is the SNAP-8 dosage from a 10 mg vial?

For topical research, dosage is a finished concentration. A complete 10 mg vial produces 0.005% active SNAP-8 in a final 200 g batch. A 50 g batch at the same concentration uses 2.5 mg.

Does 10% SNAP-8 mean 10% pure peptide?

No. In developer materials, 10% refers to a nominal 0.05% supplier solution. The finished active concentration is about 0.005%, equal to 50 ppm[6].

What conventional cream concentration has the clearest context?

The best documented example used about 0.005% active SNAP-8 twice daily for 28 days in a small manufacturer panel. It is a formulation reference, not an independently replicated treatment standard.

Can a 0.03% microneedle patch be copied as a 0.03% cream?

No direct equivalence has been established. The patch combined SNAP-8 with other actives and used 350 micrometer dissolving microneedles[1].

What route has been evaluated in human research?

Human studies and developer testing evaluated topical creams, multi-peptide serums, and purpose-built dissolving microneedle patches. This review identified no peer-reviewed human or animal injection dosing study for acetyl octapeptide-3, so topical data are not converted into an injection schedule.

Recommended Research Source

We recommend Pure Lab Peptides for research-grade SNAP-8 (10 mg). Review lot-specific identity, purity, assay, and batch documentation before designing a topical formulation study.

View Research Product

Important Research Note

Published human SNAP-8 research uses complete topical products and localized dissolving patches. Interpret each result with its vehicle, co-ingredients, delivery system, application schedule, and measurement method.

References

  • 1
    Annals of Dermatology (2024). Shin JY, et al. Split-face study of a dissolving multi-active microneedle patch containing 0.03% SNAP-8. PubMed record.
  • 2
    Journal of Cosmetic Dermatology (2020). Avcil M, et al. Clinical study of a multi-active HA microneedle patch containing acetyl octapeptide-3. PubMed record.
  • 3
    Journal of Drugs in Dermatology (2016). Draelos ZD, et al. Open-label topical multi-peptide serum and supporting regimen. Full article.
  • 4
    Journal of Cosmetic Dermatology (2023). Moy M, et al. Proprietary peptide-pro complex serum study and discussion of a 3% SNAP-8 supplier-solution cream. PubMed record.
  • 5
    Journal of Analytical Science and Technology (2020). Ji Y, et al. LC-MS/MS method for SNAP-8 in a biodegradable microneedle patch and analytical-standard stability observations. Full article.
  • 6
    Lipotec SNAP-8 ingredient documentation. Composition of the approximately 0.05% supplier solution, 3% to 10% inclusion range, and manufacturer cream testing. Developer brochure and product dossier.
  • 7
    U.S. FDA Global Substance Registration System. Validated identity and amino-acid sequence for acetyl octapeptide-3. FDA substance record.
  • 9
    Pure Lab Peptides. SNAP-8 10 mg research-product listing and batch documentation. Product listing.

Additional Research and Background

These sources provide related context and are not presented as support for a specific statement above.

  • 1
    U.S. Food and Drug Administration. FDA authority over cosmetics and the distinction between cosmetic products and approved drugs. FDA cosmetics overview.

Related research, protocols, and guides

Explore the full SNAP-8 research overview and practical peptide storage guidance. These resources support the formulation-specific calculations on this page.

Research overview

Practical guides